Non-GLP Exploratory Toxicology

Capabilities include:

• Early assessment of drug safety risk
  
  
  • Exposure, toxicokinetics and tolerability studies
  • Dose range finding studies
  • Safety biomarkers (transcriptomics, proteomics, metabolomics, lipidomics)
  • Formulation assessment

• Mechanistic toxicology studies
  
  
  • Histology
  • Haematology and biochemistry
  • mRNA analysis and upregulation in CYP activity
  • Protein expression analysis
  • Toxicogenetics

• Proof of concept for drug mechanism of action or efficacy
  
  
  • Target engagement
  • Biomarkers

Our non-GLP exploratory toxicology services are carried out at Evotec’s French facility in Toulouse. 

Contact enquiries@cyprotex.com for more information